Cientistas developed antibodies that prevented infection by the Epstein-Barr virus in laboratory models of the human immune system. The virus infects around 95% of the world’s population and remains latent in the body. The research used mice modified to produce human antibodies.
The advance focuses on proteins on the surface of the virus. One of them, called gp42, helps the pathogen enter cells. Outra, the gp350, makes initial connection easier. Human monoclonal antibodies blocked these interactions.
Anticorpos target key virus proteins
Pesquisadores of Fred Hutch Cancer Center created the antibodies in transgenic mice that carry human antibody genes. The process generated two molecules against gp350 and eight against gp42.
A specific antibody against gp42 completely prevented infection when humanized mice were exposed to the virus. Outro antibody against gp350 offered partial protection.
- Antibodies block the virus from binding to receptors on B cells.
- Eles prevent the fusion of the viral membrane with the host cell.
- The approach uses fully human antibodies to reduce rejection risks.
- Testes occurred in models with an immune system similar to that of humans.
The study was published in the journal Cell Reports Medicine. Ele represents a step forward after years of difficulty in controlling the virus’s ability to invade cells.
Vírus Epstein-Barr remains latent in most people
Initial infection with Epstein-Barr often occurs in childhood or adolescence. The virus spreads mainly through saliva. Depois of the acute phase, it is inactive inside the cells.
In some cases, the virus can reactivate when immunity weakens. Situações stress, illness, or use of immunosuppressant medications increase this risk. Transplanted Pessoas face a higher chance of serious complications.
Sintomas of primary infection include fatigue, fever, and sore throat. Most adults carry the virus without realizing it. The pathogen also appears linked to infectious mononucleosis and more serious conditions.
Ligações with cancer and chronic illnesses
Epstein-Barr is associated with several types of cancer, especially in individuals with compromised immunity. Exemplos include lymphomas and carcinomas. Pesquisas further indicates connections with neurodegenerative disorders and other long-term diseases.
Pacientes after organ or cell transplantation are at risk for post-transplant lymphoproliferative disorders. Nesses cases, the virus can lead to aggressive lymphomas. Prevention of viremia by Epstein-Barr would help reduce these problems.
Detalhes from the experiment with humanized models
The mice used in the study were engineered to have human antibody genes. Isso enabled the production of genetically human monoclonal antibodies.
Depois creation, the researchers tested the antibodies in mice with humanized immune systems. An antibody against gp42 completely prevented infection after challenge with the virus.
Structural analysis revealed sites of vulnerability on the viral surface. Esses data can guide future development of vaccines or therapies.
Potencial for preventive treatments
The authors highlight that antibodies could be used as an infusion to block infection or reactivation in high-risk groups. Transplantados and immunocompromised patients would be the main beneficiaries.
The research is still in the experimental phase. Ela needs further validation before moving into human testing. Não There is no vaccine or specific treatment approved against Epstein-Barr to date.
The work paves the way for strategies that act on the entry of the virus into cells. Diferente than traditional antiviral approaches, the focus is on early neutralization.
What the results indicate for the future
Cientistas see the study as a milestone in the search for protection against Epstein-Barr. The virus affects almost the entire population at some point in their lives. Controlar activation may reduce the impact on public health.
Próximos steps include additional safety and efficacy analyses. The scientific community follows the development of human antibodies for clinical applications.
Epstein-Barr continues to be present in most people silently. Avanços like this help to better understand its mechanisms and possible interventions.
